Cambria Biosciences Receives $5.0 Million in Grants and Awards for Neurodegenerative Disease Drug Discovery and Preclinical Development Programs

WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences, a privately held biopharmaceutical company focused on the discovery and development of innovative proprietary small molecule drugs for neurological conditions, today announced that it has been awarded five grants from multiple organizations totaling $5.0 million. The grant funding will support the company’s drug discovery programs for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), muscular dystrophy and Parkinson’s disease.